Authors’ Reply – Comments: Serum levels of infliximab in Brazilian patients with Crohn’s disease: what are the reasons for differences from previous studies? by Gomes, Luis Eduardo Miani et al.
Authors’ Reply – Comments: Serum levels of inflix-
imab in Brazilian patients with Crohn’s disease: what
are the reasons for differences from previous studies?
Luis Eduardo Miani Gomes,I Francesca Aparecida Ramos da Silva,I Lı´via Bitencourt Pascoal0000-0000-0000-0000 ,I Renato
Lazarin Ricci,I Guilherme Nogueira0000-0000-0000-0000 ,II Michel Gardere Camargo,I Maria de Lourdes Setsuko Ayrizono,I
Joa˜o Jose´ Fagundes,I Raquel Franco Leal0000-0000-0000-0000 I,*
I Laboratorio de Investigacao em Doencas Inflamatorias Intestinais, Servico de Coloproctologia, Faculdade de Ciencias Medicas, Universidade Estadual de
Campinas (UNICAMP), Campinas, SP, BR. II Laboratorio de Sinalizacao Celular, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, BR.
Gomes LEM, da Silva FAR, Pascoal LB, Ricci RL, Nogueira G, Camargo MG, et al. Authors’ Reply – Comments: Serum levels of infliximab in Brazilian patients
with Crohn’s disease: what are the reasons for differences from previous studies? Clinics. 2019;74:e1517
*Corresponding author. E-mail: rafranco.unicamp@gmail.com
To the Editor:
We would like to thank Teixeira et al. (1) for their
comments on our article (2). They correctly noted that the
majority of our patients presented infliximab (IFX) levels
above the therapeutic concentration, differing from three
other Brazilian studies published between 2017 and 2018
(3-5). However, there are several significant conceptual and
methodological differences between those studies and ours
that need to be taken into consideration to understand the
factors that led to such contrasting results. Our aim was to
perform a prospective observational study, not an interven-
tional one. Nor did we aim to establish the best minimum
and maximum cut offs of the therapeutic levels of IFX for
Brazilian Crohn’s disease (CD) patients.
In 2017, Kampa et al. (3) conducted the first Brazilian
investigation in this field (reference 10 of the Gomes et al.
Manuscript), which measured IFX levels and anti-infliximab
antibodies (ATI). However, Kampa et al. themselves
admitted that the limitations of their paper were its
retrospective character (failures in data collection might
occur) and the absence of a detailed description of the clinical
and endoscopic conditions at the moment of collection.
Additionally, the aim of Teixeira et al. (4) was to measure the
serum levels of IFX by comparing two different, already
validated, assays (6,7). Although this approach was indeed
interesting, the majority of patients included in the study
(88%) were in remission, a condition that is not impacted
by therapeutic drug monitoring in clinical practice.
Teixeira et al. (4) even suggested that more studies on
patients with active disease would be necessary. Finally,
Parra et al. (5) evaluated the levels of IFX in a larger cohort
of 55 patients with CD and 16 with UC. The novelty of this
study was the use of a quality of life questionnaire and its
correlation with the serum trough levels of IFX. Although
they did perform their analysis considering patients in a
state of disease activity or remission, the criterion for
disease activity was based on an elective colonoscopy
examination performed at least three months before and
three months after blood collection. This interval can be
deemed rather too long in the case of inflammatory bowel
diseases. By contrast, we only took into consideration
the interval of up to one month before or after sample
collection. Moreover, as acknowledged by Parra et al. (5)
themselves, they did not include variables for either
proinflammatory biomarkers (such as CRP and fecal
calprotectin) or body mass index (BMI) in their analysis.
We assessed the serum albumin levels of all patients inclu-
ded in our research.
All of the studies cited above performed analyses that
included patients with CD and ulcerative colitis (UC). Our
study included only CD patients because the molecular
characteristics of each disease may differ in response to a
specific drug. For histological healing, for example, the IFX
trough level requirement for CD cases is X9.8 mg/mL,
whereas it is X10.5 mg/L for UC patients (8,9).
Our study is the first Brazilian prospective observational
study to measure the levels of IFX and ATIs in CD patients,
assessing disease activity by colonoscopy or nuclear mag-
netic resonance (NMR), including in the analysis at least one
nutritional parameter (albumin level) that is relevant to the
drug pharmacokinetics (10) (reference 27 of the Gomes et al.
manuscript). Therefore, it should not at all come as a surprise
that patients with a relatively favorable nutritional para-
meter, such as albumin, present adequate or supratherapeu-
tic levels of IFX in both groups (active and in remission).
Recently, we published a paper regarding the nutritional
aspects of 60 CD patients receiving treatment at our insti-
tution (11). Although relevant differences were observed in
nutritional markers for patients in remission and with active
disease, the prealbumin serum levels did not differ between
these groups. We emphasize the need for a multidisciplinary
team, including nutritional follow-up, so that these patients
can achieve better outcomes.
Regarding the therapeutic window noted by Teixeira et al.
(1), Ungar et al. (12) found a significant association between
anti-TNF-a serum levels and mucosal healing, which led toDOI: 10.6061/clinics/2019/e1517
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the recommendation that a serum level of 6-10 mg/mL for
IFX is necessary to achieve healing of 80%-90% of IBD
patients, which may be considered a therapeutic window as
well. Moreover, this interval was followed in other studies in
the literature (13-15). Some authors propose minimum levels
of up to 10 mg/mL or even 18 mg/mL for fistula healing
(12,14). Drobne et al. recently observed that maintaining
higher infliximab levels 47 mg/mL provided better control
of IBD without an increased risk of infection (13). Our choice
for the quantitative ELISA from Promonitors (Progenika
Biophama, S. A. Spain) was due to its widespread use in
other institutions around the world and its greater avail-
ability for purchase in our location, in addition to the
possibility to perform the ELISA test in our laboratory and to
standardize the technique without the need to send samples
abroad, which would involve high costs and additional
approvals by national research ethical committees.
Concerning the comments of Teixeira et al. (1) about why
we might have mixed the results of the study because several
patients with levels between 3-6 mg/mL would be consid-
ered adequate according to the range of 3-7 mg/mL but
infratherapeutic according to our adopted range (6-10 mg/
mL), we would like to clarify that, as described in our
manuscript (2), there were no patients with levels between 3-
6 mg/mL. Of the few patients we had with IFX trough levels
p 5 mg/mL, all presented undetectable levels (o0.035 mg/
mL), and they correlated 100% with positive ATIs, demon-
strating the accuracy of the test.
Concerning the similar anti-TNFa levels that we observed
in both the active disease and remission groups (2), other
studies in the literature have already noted this phenomenon
(16,17). Patients with active mucosal disease may present a
higher rate of serum-to-tissue drug level mismatch compared
to those in remission (17). This kind of analysis may be more
relevant to explain the correlation between therapeutic drug
monitoring and the presence of intestinal inflammation,
rather than the simple isolated serum drug level. Low serum
drug levels may not always correlate with patients in terms
of disease activity because they may depend more on the
ratio of serum and tissue levels than on only serum levels.
Although there was no correlation with CD activity in our
study, the IFX and ATIs levels correlated with each other
(all patients with undetectable levels of IFX had positive or
close to positive ATI levels), as described in our study. This
scenario may be important in patients with active disease to
improve their clinical management.
For all of these reasons, unfortunately, the previous
Brazilian studies mentioned above are sufficiently different
from ours to render them not at all comparable. However,
the apparent discrepancy between our results and theirs
indicates the need for further dialogue in the field concerning
different fundamental approaches. Prospective studies that
assess IFX and ATIs levels at more than one point in time (18)
(reference 33 of the Gomes et al. manuscript), in addition to
performing validated assays in our own Brazilian institu-
tions, may bring the results closer to the reality of clinical
practice. A prospective study analyzing IFX levels by two
different assays (one of them a rapid test), and detecting ATIs
levels is ongoing at our institution to better clarify our
findings and to determine how much they may help in the
management of CD.
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